SB 3221

Select Language
  ×
The Illinois General Assembly offers the Google Translate™ service for visitor convenience. In no way should it be considered accurate as to the translation of any content herein.
Visitors of the Illinois General Assembly website are encouraged to use other translation services available on the internet.
The English language version is always the official and authoritative version of this website.
NOTE: To return to the original English language version, select the "Show Original" button on the Google Translate™ menu bar at the top of the window.
  Choose Language
  English
  Afrikaans
  Albanian
  Arabic
  Armenian
  Azerbaijani
  Basque
  Bengali
  Bosnian
  Catalan
  Croatian
  Czech
  Danish
  Dutch
  Esperanto
  Estonian
  Filipino
  Finnish
  French
  Galician
  Georgian
  German
  Greek
  Gujarati
  Haitian Creole
  Hausa
  Hawaiian
  Hebrew
  Hindi
  Hungarian
  Icelandic
  Indonesian
  Interlingua
  Interlingue
  Inuktitut
  Irish
  Italian
  Japanese
  Javanese
  Kannada
  Khmer
  Korean
  Latin
  Latvian
  Lithuanian
  Luxembourgish
  Macedonian
  Malagasy
  Malayalam
  Maltese
  Maori
  Marathi
  Myanmar
  Nepali
  Norwegian
  Odia
  Pashto
  Punjabi
  Romanian
  Russian
  Samoan
  Sango
  Sanskrit
  Sardinian
  Sindhi
  Sinhala
  Slovak
  Slovenian
  Somali
  Southern Sotho
  Spanish
  Sundanese
  Swahili
  Swedish
  Tamil
  Telugu
  Thai
  Tigrinya
  Tonga
  Turkish
  Ukrainian
  Urdu
  Vietnamese
  Welsh
  Xhosa
  Yiddish
  Yoruba
  Zulu
  Powered by Translate
  Close
Illinois General Assembly
Top Navigation Bar
  Translate
  Learn
  Select General Assembly
  Search the 104th General Assembly
  Enter search terms for legislation, members, committees, or schedules.
  ILGA.GOV
Mobile Top Bar
  Search the 104th General Assembly
  Enter keywords to search the Illinois General Assembly website.
Full Text of SB3221
Home
Legislation
Full Text
	SB3221 - 104th General Assembly
		Bill Status
		Full Text
		Votes
		Witness Slips
	Select Menu
	Bill Status
	Full Text
	Votes
	Witness Slips
	Printer Friendly Version
			Introduced
		Printer Friendly Version
		Introduced
			 Open PDF
104TH GENERAL ASSEMBLY
State of Illinois
2025 and 2026
SB3221
Introduced 2/2/2026, by Sen. Julie A. Morrison
SYNOPSIS AS INTRODUCED:
720 ILCS 570/102	  from Ch. 56 1/2, par. 1102
720 ILCS 570/204	  from Ch. 56 1/2, par. 1204
720 ILCS 570/206	  from Ch. 56 1/2, par. 1206
720 ILCS 570/208	  from Ch. 56 1/2, par. 1208
720 ILCS 570/309.1 new
Amends the Illinois Controlled Substances Act. Makes structural and other changes to the list of controlled substances. Adds xylazine as a Class III controlled substance. Provides that notwithstanding the scheduling of xylazine as a Schedule III controlled substance, xylazine shall not be considered a controlled substance when: (1) used by licensed Illinois veterinarians dispensing or prescribing for, or administering to, a nonhuman species of a drug containing xylazine that has been approved by the U.S. Food and Drug Administration; (2) used by licensed Illinois veterinarians dispensing or prescribing for, or administering to, a nonhuman species that is permissible under the Federal Food, Drug, and Cosmetic Act; (3) manufactured, distributed, or used as an active pharmaceutical ingredient for manufacturing an animal drug approved under the Federal Food, Drug, and Cosmetic Act; (4) used by a licensed certified euthanasia technician employed by a certified euthanasia agency; or (5) used by a wildlife biologist engaged in legal or authorized fieldwork under the indirect supervision of a veterinarian. Defines "isomer". Effective January 1, 2027.
LRB104 20204 RLC 33655 b
A BILL FOR
		SB3221		LRB104 20204 RLC 33655 b
1    AN ACT concerning criminal law.
2    Be it enacted by the People of the State of Illinois,
3represented in the General Assembly:
4    Section 5. The Illinois Controlled Substances Act is
5amended by changing Sections 102, 204, 206, and 208 and by
6adding Section 309.1 as follows:
7    (720 ILCS 570/102)  (from Ch. 56 1/2, par. 1102)
8    Sec. 102. Definitions.  As used in this Act, unless the
9context otherwise requires:
10    (a) "Person with a substance use disorder" means any
11person who has a substance use disorder diagnosis defined as a
12spectrum of persistent and recurring problematic behavior that
13encompasses 10 separate classes of drugs: alcohol; caffeine;
14cannabis; hallucinogens; inhalants; opioids; sedatives,
15hypnotics and anxiolytics; stimulants; and tobacco; and other
16unknown substances leading to clinically significant
17impairment or distress.
18    (b) "Administer" means the direct application of a
19controlled substance, whether by injection, inhalation,
20ingestion, or any other means, to the body of a patient,
21research subject, or animal (as defined by the Humane
22Euthanasia in Animal Shelters Act) by:
23        (1) a practitioner (or, in his or her presence, by his
		SB3221	- 2 -	LRB104 20204 RLC 33655 b
1    or her authorized agent),
2        (2) the patient or research subject pursuant to an
3    order, or
4        (3) a euthanasia technician as defined by the Humane
5    Euthanasia in Animal Shelters Act.
6    (c) "Agent" means an authorized person who acts on behalf
7of or at the direction of a manufacturer, distributor,
8dispenser, prescriber, or practitioner. It does not include a
9common or contract carrier, public warehouseman or employee of
10the carrier or warehouseman.
11    (c-1) "Anabolic Steroids" means any drug or hormonal
12substance, chemically and pharmacologically related to
13testosterone (other than estrogens, progestins,
14corticosteroids, and dehydroepiandrosterone), and includes:
15    (i) 3[beta],17-dihydroxy-5a-androstane, 
16    (ii) 3[alpha],17[beta]-dihydroxy-5a-androstane, 
17    (iii) 5[alpha]-androstan-3,17-dione, 
18    (iv) 1-androstenediol (3[beta], 
19        17[beta]-dihydroxy-5[alpha]-androst-1-ene), 
20    (v) 1-androstenediol (3[alpha], 
21        17[beta]-dihydroxy-5[alpha]-androst-1-ene), 
22    (vi) 4-androstenediol  
23        (3[beta],17[beta]-dihydroxy-androst-4-ene), 
24    (vii) 5-androstenediol  
25        (3[beta],17[beta]-dihydroxy-androst-5-ene), 
26    (viii) 1-androstenedione  
		SB3221	- 3 -	LRB104 20204 RLC 33655 b
1        ([5alpha]-androst-1-en-3,17-dione), 
2    (ix) 4-androstenedione  
3        (androst-4-en-3,17-dione), 
4    (x) 5-androstenedione  
5        (androst-5-en-3,17-dione), 
6    (xi) bolasterone (7[alpha],17a-dimethyl-17[beta]- 
7        hydroxyandrost-4-en-3-one), 
8    (xii) boldenone (17[beta]-hydroxyandrost- 
9        1,4,-diene-3-one), 
10    (xiii) boldione (androsta-1,4- 
11        diene-3,17-dione), 
12    (xiv) calusterone (7[beta],17[alpha]-dimethyl-17 
13        [beta]-hydroxyandrost-4-en-3-one), 
14    (xv) clostebol (4-chloro-17[beta]- 
15        hydroxyandrost-4-en-3-one), 
16    (xvi) dehydrochloromethyltestosterone (4-chloro- 
17        17[beta]-hydroxy-17[alpha]-methyl- 
18        androst-1,4-dien-3-one), 
19    (xvii) desoxymethyltestosterone 
20    (17[alpha]-methyl-5[alpha] 
21        -androst-2-en-17[beta]-ol)(a.k.a., madol), 
22    (xviii) [delta]1-dihydrotestosterone (a.k.a.  
23        '1-testosterone') (17[beta]-hydroxy- 
24        5[alpha]-androst-1-en-3-one), 
25    (xix) 4-dihydrotestosterone (17[beta]-hydroxy- 
26        androstan-3-one), 
		SB3221	- 4 -	LRB104 20204 RLC 33655 b
1    (xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl- 
2        5[alpha]-androstan-3-one), 
3    (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]- 
4        hydroxyestr-4-ene), 
5    (xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl- 
6        1[beta],17[beta]-dihydroxyandrost-4-en-3-one), 
7    (xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha], 
8        17[beta]-dihydroxyandrost-1,4-dien-3-one), 
9    (xxiv) furazabol (17[alpha]-methyl-17[beta]- 
10        hydroxyandrostano[2,3-c]-furazan), 
11    (xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one, 
12    (xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy- 
13        androst-4-en-3-one), 
14    (xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]- 
15        dihydroxy-estr-4-en-3-one), 
16    (xxviii) mestanolone (17[alpha]-methyl-17[beta]- 
17        hydroxy-5-androstan-3-one), 
18    (xxix) mesterolone (1amethyl-17[beta]-hydroxy- 
19        [5a]-androstan-3-one), 
20    (xxx) methandienone (17[alpha]-methyl-17[beta]- 
21        hydroxyandrost-1,4-dien-3-one), 
22    (xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]- 
23        dihydroxyandrost-5-ene), 
24    (xxxii) methenolone (1-methyl-17[beta]-hydroxy- 
25        5[alpha]-androst-1-en-3-one), 
26    (xxxiii) 17[alpha]-methyl-3[beta], 17[beta]- 
		SB3221	- 5 -	LRB104 20204 RLC 33655 b
1        dihydroxy-5a-androstane, 
2    (xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy 
3        -5a-androstane, 
4    (xxxv) 17[alpha]-methyl-3[beta],17[beta]- 
5        dihydroxyandrost-4-ene), 
6    (xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]- 
7        methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one), 
8    (xxxvii) methyldienolone (17[alpha]-methyl-17[beta]- 
9        hydroxyestra-4,9(10)-dien-3-one), 
10    (xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]- 
11        hydroxyestra-4,9-11-trien-3-one), 
12    (xxxix) methyltestosterone (17[alpha]-methyl-17[beta]- 
13        hydroxyandrost-4-en-3-one), 
14    (xl) mibolerone (7[alpha],17a-dimethyl-17[beta]- 
15        hydroxyestr-4-en-3-one), 
16    (xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone  
17        (17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]- 
18        androst-1-en-3-one)(a.k.a. '17-[alpha]-methyl- 
19        1-testosterone'), 
20    (xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one), 
21    (xliii) 19-nor-4-androstenediol (3[beta], 17[beta]- 
22        dihydroxyestr-4-ene), 
23    (xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]- 
24        dihydroxyestr-4-ene), 
25    (xlv) 19-nor-5-androstenediol (3[beta], 17[beta]- 
26        dihydroxyestr-5-ene), 
		SB3221	- 6 -	LRB104 20204 RLC 33655 b
1    (xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]- 
2        dihydroxyestr-5-ene), 
3    (xlvii) 19-nor-4,9(10)-androstadienedione  
4        (estra-4,9(10)-diene-3,17-dione), 
5    (xlviii) 19-nor-4-androstenedione (estr-4- 
6        en-3,17-dione), 
7    (xlix) 19-nor-5-androstenedione (estr-5- 
8        en-3,17-dione), 
9    (l) norbolethone (13[beta], 17a-diethyl-17[beta]- 
10        hydroxygon-4-en-3-one), 
11    (li) norclostebol (4-chloro-17[beta]- 
12        hydroxyestr-4-en-3-one), 
13    (lii) norethandrolone (17[alpha]-ethyl-17[beta]- 
14        hydroxyestr-4-en-3-one), 
15    (liii) normethandrolone (17[alpha]-methyl-17[beta]- 
16        hydroxyestr-4-en-3-one), 
17    (liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy- 
18        2-oxa-5[alpha]-androstan-3-one), 
19    (lv) oxymesterone (17[alpha]-methyl-4,17[beta]- 
20        dihydroxyandrost-4-en-3-one), 
21    (lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene- 
22        17[beta]-hydroxy-(5[alpha]-androstan-3-one), 
23    (lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy- 
24        (5[alpha]-androst-2-eno[3,2-c]-pyrazole), 
25    (lviii) stenbolone (17[beta]-hydroxy-2-methyl- 
26        (5[alpha]-androst-1-en-3-one), 
		SB3221	- 7 -	LRB104 20204 RLC 33655 b
1    (lix) testolactone (13-hydroxy-3-oxo-13,17- 
2        secoandrosta-1,4-dien-17-oic 
3        acid lactone), 
4    (lx) testosterone (17[beta]-hydroxyandrost- 
5        4-en-3-one), 
6    (lxi) tetrahydrogestrinone (13[beta], 17[alpha]- 
7        diethyl-17[beta]-hydroxygon- 
8        4,9,11-trien-3-one), 
9    (lxii) trenbolone (17[beta]-hydroxyestr-4,9, 
10        11-trien-3-one). 
11    Any person who is otherwise lawfully in possession of an
12anabolic steroid, or who otherwise lawfully manufactures,
13distributes, dispenses, delivers, or possesses with intent to
14deliver an anabolic steroid, which anabolic steroid is
15expressly intended for and lawfully allowed to be administered
16through implants to livestock or other nonhuman species, and
17which is approved by the Secretary of Health and Human
18Services for such administration, and which the person intends
19to administer or have administered through such implants,
20shall not be considered to be in unauthorized possession or to
21unlawfully manufacture, distribute, dispense, deliver, or
22possess with intent to deliver such anabolic steroid for
23purposes of this Act.
24    (d) "Administration" means the Drug Enforcement
25Administration, United States Department of Justice, or its
26successor agency.
		SB3221	- 8 -	LRB104 20204 RLC 33655 b
1    (d-5) "Clinical Director, Prescription Monitoring Program"
2means a Department of Human Services administrative employee
3licensed to either prescribe or dispense controlled substances
4who shall run the clinical aspects of the Department of Human
5Services Prescription Monitoring Program and its Prescription
6Information Library.
7    (d-10) "Compounding" means the preparation and mixing of
8components, excluding flavorings, (1) as the result of a
9prescriber's prescription drug order or initiative based on
10the prescriber-patient-pharmacist relationship in the course
11of professional practice or (2) for the purpose of, or
12incident to, research, teaching, or chemical analysis and not
13for sale or dispensing. "Compounding" includes the preparation
14of drugs or devices in anticipation of receiving prescription
15drug orders based on routine, regularly observed dispensing
16patterns. Commercially available products may be compounded
17for dispensing to individual patients only if both of the
18following conditions are met: (i) the commercial product is
19not reasonably available from normal distribution channels in
20a timely manner to meet the patient's needs and (ii) the
21prescribing practitioner has requested that the drug be
22compounded.
23    (e) "Control" means to add a drug or other substance, or
24immediate precursor, to a Schedule whether by transfer from
25another Schedule or otherwise.
26    (f) "Controlled Substance" means (i) a drug, substance,
		SB3221	- 9 -	LRB104 20204 RLC 33655 b
1immediate precursor, or synthetic drug in the Schedules of
2Article II of this Act or (ii) a drug or other substance, or
3immediate precursor, designated as a controlled substance by
4the Department through administrative rule. The term does not
5include distilled spirits, wine, malt beverages, or tobacco,
6as those terms are defined or used in the Liquor Control Act of
71934 and the Tobacco Products Tax Act of 1995.
8    (f-5) "Controlled substance analog" means a substance:
9        (1) the chemical structure of which is substantially
10    similar to the chemical structure of a controlled
11    substance in Schedule I or II;
12        (2) which has a stimulant, depressant, or
13    hallucinogenic effect on the central nervous system that
14    is substantially similar to or greater than the stimulant,
15    depressant, or hallucinogenic effect on the central
16    nervous system of a controlled substance in Schedule I or
17    II; or
18        (3) with respect to a particular person, which such
19    person represents or intends to have a stimulant,
20    depressant, or hallucinogenic effect on the central
21    nervous system that is substantially similar to or greater
22    than the stimulant, depressant, or hallucinogenic effect
23    on the central nervous system of a controlled substance in
24    Schedule I or II.
25    (g) "Counterfeit substance" means a controlled substance,
26which, or the container or labeling of which, without
		SB3221	- 10 -	LRB104 20204 RLC 33655 b
1authorization bears the trademark, trade name, or other
2identifying mark, imprint, number or device, or any likeness
3thereof, of a manufacturer, distributor, or dispenser other
4than the person who in fact manufactured, distributed, or
5dispensed the substance.
6    (h) "Deliver" or "delivery" means the actual, constructive
7or attempted transfer of possession of a controlled substance,
8with or without consideration, whether or not there is an
9agency relationship. "Deliver" or "delivery" does not include
10the donation of drugs to the extent permitted under the
11Illinois Drug Reuse Opportunity Program Act.
12    (i) "Department" means the Illinois Department of Human
13Services (as successor to the Department of Alcoholism and
14Substance Abuse) or its successor agency.
15    (j) (Blank).
16    (k) "Department of Corrections" means the Department of
17Corrections of the State of Illinois or its successor agency.
18    (l) "Department of Financial and Professional Regulation"
19means the Department of Financial and Professional Regulation
20of the State of Illinois or its successor agency.
21    (m) "Depressant" means any drug that (i) causes an overall
22depression of central nervous system functions, (ii) causes
23impaired consciousness and awareness, and (iii) can be
24habit-forming or lead to a substance misuse or substance use
25disorder, including, but not limited to, alcohol, cannabis and
26its active principles and their analogs, benzodiazepines and
		SB3221	- 11 -	LRB104 20204 RLC 33655 b
1their analogs, barbiturates and their analogs, opioids
2(natural and synthetic) and their analogs, and chloral hydrate
3and similar sedative hypnotics.
4    (n) (Blank).
5    (o) "Director" means the Director of the Illinois State
6Police or his or her designated agents.
7    (p) "Dispense" means to deliver a controlled substance to
8an ultimate user or research subject by or pursuant to the
9lawful order of a prescriber, including the prescribing,
10administering, packaging, labeling, or compounding necessary
11to prepare the substance for that delivery.
12    (q) "Dispenser" means a practitioner who dispenses.
13    (r) "Distribute" means to deliver, other than by
14administering or dispensing, a controlled substance.
15    (s) "Distributor" means a person who distributes.
16    (t) "Drug" means (1) substances recognized as drugs in the
17official United States Pharmacopoeia, Official Homeopathic
18Pharmacopoeia of the United States, or official National
19Formulary, or any supplement to any of them; (2) substances
20intended for use in diagnosis, cure, mitigation, treatment, or
21prevention of disease in man or animals; (3) substances (other
22than food) intended to affect the structure of any function of
23the body of man or animals and (4) substances intended for use
24as a component of any article specified in clause (1), (2), or
25(3) of this subsection. It does not include devices or their
26components, parts, or accessories.
		SB3221	- 12 -	LRB104 20204 RLC 33655 b
1    (t-3) "Electronic health record" or "EHR" means an
2electronic record of health-related information on an
3individual that is created, gathered, managed, and consulted
4by authorized health care clinicians and staff.
5    (t-3.5) "Electronic health record system" or "EHR system"
6means any computer-based system or combination of federally
7certified Health IT Modules (defined at 42 CFR 170.102 or its
8successor) used as a repository for electronic health records
9and accessed or updated by a prescriber or authorized
10surrogate in the ordinary course of his or her medical
11practice. For purposes of connecting to the Prescription
12Information Library maintained by the Bureau of Pharmacy and
13Clinical Support Systems or its successor, an EHR system may
14connect to the Prescription Information Library directly or
15through all or part of a computer program or system that is a
16federally certified Health IT Module maintained by a third
17party and used by the EHR system to secure access to the
18database.
19    (t-4) "Emergency medical services personnel" has the
20meaning ascribed to it in the Emergency Medical Services (EMS)
21Systems Act.
22    (t-5) "Euthanasia agency" means an entity certified by the
23Department of Financial and Professional Regulation for the
24purpose of animal euthanasia that holds an animal control
25facility license or animal shelter license under the Animal
26Welfare Act. A euthanasia agency is authorized to purchase,
		SB3221	- 13 -	LRB104 20204 RLC 33655 b
1store, possess, and utilize Schedule II nonnarcotic and
2Schedule III nonnarcotic drugs for the sole purpose of animal
3euthanasia.
4    (t-10) "Euthanasia drugs" means Schedule II or Schedule
5III substances (nonnarcotic controlled substances) that are
6used by a euthanasia agency for the purpose of animal
7euthanasia.
8    (u) "Good faith" means the prescribing or dispensing of a
9controlled substance by a practitioner in the regular course
10of professional treatment to or for any person who is under his
11or her treatment for a pathology or condition other than that
12individual's physical or psychological dependence upon a
13controlled substance, except as provided herein: and
14application of the term to a pharmacist shall mean the
15dispensing of a controlled substance pursuant to the
16prescriber's order which in the professional judgment of the
17pharmacist is lawful. The pharmacist shall be guided by
18accepted professional standards, including, but not limited
19to, the following, in making the judgment:
20        (1) lack of consistency of prescriber-patient
21    relationship,
22        (2) frequency of prescriptions for same drug by one
23    prescriber for large numbers of patients,
24        (3) quantities beyond those normally prescribed,
25        (4) unusual dosages (recognizing that there may be
26    clinical circumstances where more or less than the usual
		SB3221	- 14 -	LRB104 20204 RLC 33655 b
1    dose may be used legitimately),
2        (5) unusual geographic distances between patient,
3    pharmacist and prescriber,
4        (6) consistent prescribing of habit-forming drugs.
5    (u-0.5) "Hallucinogen" means a drug that causes markedly
6altered sensory perception leading to hallucinations of any
7type.
8    (u-1) "Home infusion services" means services provided by
9a pharmacy in compounding solutions for direct administration
10to a patient in a private residence, long-term care facility,
11or hospice setting by means of parenteral, intravenous,
12intramuscular, subcutaneous, or intraspinal infusion.
13    (u-5) "Illinois State Police" means the Illinois State
14Police or its successor agency.
15    (v) "Immediate precursor" means a substance:
16        (1) which the Department has found to be and by rule
17    designated as being a principal compound used, or produced
18    primarily for use, in the manufacture of a controlled
19    substance;
20        (2) which is an immediate chemical intermediary used
21    or likely to be used in the manufacture of such controlled
22    substance; and
23        (3) the control of which is necessary to prevent,
24    curtail or limit the manufacture of such controlled
25    substance.
26    (w) "Instructional activities" means the acts of teaching,
		SB3221	- 15 -	LRB104 20204 RLC 33655 b
1educating or instructing by practitioners using controlled
2substances within educational facilities approved by the State
3Board of Education or its successor agency.
4    (w-1) "Isomer" means optical isomer, unless specifically 
5detailed in this Act.
6    (x) "Local authorities" means a duly organized State,
7County or Municipal peace unit or police force.
8    (y) "Look-alike substance" means a substance, other than a
9controlled substance which (1) by overall dosage unit
10appearance, including shape, color, size, markings or lack
11thereof, taste, consistency, or any other identifying physical
12characteristic of the substance, would lead a reasonable
13person to believe that the substance is a controlled
14substance, or (2) is expressly or impliedly represented to be
15a controlled substance or is distributed under circumstances
16which would lead a reasonable person to believe that the
17substance is a controlled substance. For the purpose of
18determining whether the representations made or the
19circumstances of the distribution would lead a reasonable
20person to believe the substance to be a controlled substance
21under this clause (2) of subsection (y), the court or other
22authority may consider the following factors in addition to
23any other factor that may be relevant:
24        (a) statements made by the owner or person in control
25    of the substance concerning its nature, use or effect;
26        (b) statements made to the buyer or recipient that the
		SB3221	- 16 -	LRB104 20204 RLC 33655 b
1    substance may be resold for profit;
2        (c) whether the substance is packaged in a manner
3    normally used for the illegal distribution of controlled
4    substances;
5        (d) whether the distribution or attempted distribution
6    included an exchange of or demand for money or other
7    property as consideration, and whether the amount of the
8    consideration was substantially greater than the
9    reasonable retail market value of the substance.
10    Clause (1) of this subsection (y) shall not apply to a
11noncontrolled substance in its finished dosage form that was
12initially introduced into commerce prior to the initial
13introduction into commerce of a controlled substance in its
14finished dosage form which it may substantially resemble.
15    Nothing in this subsection (y) prohibits the dispensing or
16distributing of noncontrolled substances by persons authorized
17to dispense and distribute controlled substances under this
18Act, provided that such action would be deemed to be carried
19out in good faith under subsection (u) if the substances
20involved were controlled substances.
21    Nothing in this subsection (y) or in this Act prohibits
22the manufacture, preparation, propagation, compounding,
23processing, packaging, advertising or distribution of a drug
24or drugs by any person registered pursuant to Section 510 of
25the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).
26    (y-1) "Mail-order pharmacy" means a pharmacy that is
		SB3221	- 17 -	LRB104 20204 RLC 33655 b
1located in a state of the United States that delivers,
2dispenses or distributes, through the United States Postal
3Service or other common carrier, to Illinois residents, any
4substance which requires a prescription.
5    (z) "Manufacture" means the production, preparation,
6propagation, compounding, conversion or processing of a
7controlled substance other than methamphetamine, either
8directly or indirectly, by extraction from substances of
9natural origin, or independently by means of chemical
10synthesis, or by a combination of extraction and chemical
11synthesis, and includes any packaging or repackaging of the
12substance or labeling of its container, except that this term
13does not include:
14        (1) by an ultimate user, the preparation or
15    compounding of a controlled substance for his or her own
16    use;
17        (2) by a practitioner, or his or her authorized agent
18    under his or her supervision, the preparation,
19    compounding, packaging, or labeling of a controlled
20    substance:
21            (a) as an incident to his or her administering or
22        dispensing of a controlled substance in the course of
23        his or her professional practice; or
24            (b) as an incident to lawful research, teaching or
25        chemical analysis and not for sale; or
26        (3) the packaging, repackaging, or labeling of drugs
		SB3221	- 18 -	LRB104 20204 RLC 33655 b
1    only to the extent permitted under the Illinois Drug Reuse
2    Opportunity Program Act.
3    (z-1) (Blank).
4    (z-5) "Medication shopping" means the conduct prohibited
5under subsection (a) of Section 314.5 of this Act.
6    (z-10) "Mid-level practitioner" means (i) a physician
7assistant who has been delegated authority to prescribe
8through a written delegation of authority by a physician
9licensed to practice medicine in all of its branches, in
10accordance with Section 7.5 of the Physician Assistant
11Practice Act of 1987, (ii) an advanced practice registered
12nurse who has been delegated authority to prescribe through a
13written delegation of authority by a physician licensed to
14practice medicine in all of its branches or by a podiatric
15physician, in accordance with Section 65-40 of the Nurse
16Practice Act, (iii) an advanced practice registered nurse
17certified as a nurse practitioner, nurse midwife, or clinical
18nurse specialist who has been granted authority to prescribe
19by a hospital affiliate in accordance with Section 65-45 of
20the Nurse Practice Act, (iv) an animal euthanasia agency, or
21(v) a prescribing psychologist.
22    (aa) "Narcotic drug" means any of the following, whether
23produced directly or indirectly by extraction from substances
24of vegetable origin, or independently by means of chemical
25synthesis, or by a combination of extraction and chemical
26synthesis:
		SB3221	- 19 -	LRB104 20204 RLC 33655 b
1        (1) opium, opiates, derivatives of opium and opiates,
2    including their isomers, esters, ethers, salts, and salts
3    of isomers, esters, and ethers, whenever the existence of
4    such isomers, esters, ethers, and salts is possible within
5    the specific chemical designation; however the term
6    "narcotic drug" does not include the isoquinoline
7    alkaloids of opium;
8        (2) (blank);
9        (3) opium poppy and poppy straw;
10        (4) coca leaves, except coca leaves and extracts of
11    coca leaves from which substantially all of the cocaine
12    and ecgonine, and their isomers, derivatives and salts,
13    have been removed;
14        (5) cocaine, its salts, optical and geometric isomers,
15    and salts of isomers;
16        (6) ecgonine, its derivatives, their salts, isomers,
17    and salts of isomers;
18        (7) any compound, mixture, or preparation which
19    contains any quantity of any of the substances referred to
20    in subparagraphs (1) through (6).
21    (bb) "Nurse" means a registered nurse licensed under the
22Nurse Practice Act.
23    (cc) (Blank).
24    (dd) "Opiate" means a drug derived from or related to
25opium.
26    (ee) "Opium poppy" means the plant of the species Papaver
		SB3221	- 20 -	LRB104 20204 RLC 33655 b
1somniferum L., except its seeds.
2    (ee-5) "Oral dosage" means a tablet, capsule, elixir, or
3solution or other liquid form of medication intended for
4administration by mouth, but the term does not include a form
5of medication intended for buccal, sublingual, or transmucosal
6administration.
7    (ff) "Parole and Pardon Board" means the Parole and Pardon
8Board of the State of Illinois or its successor agency.
9    (gg) "Person" means any individual, corporation,
10mail-order pharmacy, government or governmental subdivision or
11agency, business trust, estate, trust, partnership or
12association, or any other entity.
13    (hh) "Pharmacist" means any person who holds a license or
14certificate of registration as a registered pharmacist, a
15local registered pharmacist or a registered assistant
16pharmacist under the Pharmacy Practice Act.
17    (ii) "Pharmacy" means any store, ship or other place in
18which pharmacy is authorized to be practiced under the
19Pharmacy Practice Act.
20    (ii-5) "Pharmacy shopping" means the conduct prohibited
21under subsection (b) of Section 314.5 of this Act.
22    (ii-10) "Physician" (except when the context otherwise
23requires) means a person licensed to practice medicine in all
24of its branches.
25    (jj) "Poppy straw" means all parts, except the seeds, of
26the opium poppy, after mowing.
		SB3221	- 21 -	LRB104 20204 RLC 33655 b
1    (kk) "Practitioner" means a physician licensed to practice
2medicine in all its branches, dentist, optometrist, podiatric
3physician, veterinarian, scientific investigator, pharmacist,
4physician assistant, advanced practice registered nurse,
5licensed practical nurse, registered nurse, emergency medical
6services personnel, hospital, laboratory, or pharmacy, or
7other person licensed, registered, or otherwise lawfully
8permitted by the United States or this State to distribute,
9dispense, conduct research with respect to, administer or use
10in teaching or chemical analysis, a controlled substance in
11the course of professional practice or research.
12    (ll) "Pre-printed prescription" means a written
13prescription upon which the designated drug has been indicated
14prior to the time of issuance; the term does not mean a written
15prescription that is individually generated by machine or
16computer in the prescriber's office.
17    (mm) "Prescriber" means a physician licensed to practice
18medicine in all its branches, dentist, optometrist,
19prescribing psychologist licensed under Section 4.2 of the
20Clinical Psychologist Licensing Act with prescriptive
21authority delegated under Section 4.3 of the Clinical
22Psychologist Licensing Act, podiatric physician, or
23veterinarian who issues a prescription, a physician assistant
24who issues a prescription for a controlled substance in
25accordance with Section 303.05, a written delegation, and a
26written collaborative agreement required under Section 7.5 of
		SB3221	- 22 -	LRB104 20204 RLC 33655 b
1the Physician Assistant Practice Act of 1987, an advanced
2practice registered nurse with prescriptive authority
3delegated under Section 65-40 of the Nurse Practice Act and in
4accordance with Section 303.05, a written delegation, and a
5written collaborative agreement under Section 65-35 of the
6Nurse Practice Act, an advanced practice registered nurse
7certified as a nurse practitioner, nurse midwife, or clinical
8nurse specialist who has been granted authority to prescribe
9by a hospital affiliate in accordance with Section 65-45 of
10the Nurse Practice Act and in accordance with Section 303.05,
11or an advanced practice registered nurse certified as a nurse
12practitioner, nurse midwife, or clinical nurse specialist who
13has full practice authority pursuant to Section 65-43 of the
14Nurse Practice Act.
15    (nn) "Prescription" means a written, facsimile, or oral
16order, or an electronic order that complies with applicable
17federal requirements, of a physician licensed to practice
18medicine in all its branches, dentist, podiatric physician or
19veterinarian for any controlled substance, of an optometrist
20in accordance with Section 15.1 of the Illinois Optometric
21Practice Act of 1987, of a prescribing psychologist licensed
22under Section 4.2 of the Clinical Psychologist Licensing Act
23with prescriptive authority delegated under Section 4.3 of the
24Clinical Psychologist Licensing Act, of a physician assistant
25for a controlled substance in accordance with Section 303.05,
26a written delegation, and a written collaborative agreement
		SB3221	- 23 -	LRB104 20204 RLC 33655 b
1required under Section 7.5 of the Physician Assistant Practice
2Act of 1987, of an advanced practice registered nurse with
3prescriptive authority delegated under Section 65-40 of the
4Nurse Practice Act who issues a prescription for a controlled
5substance in accordance with Section 303.05, a written
6delegation, and a written collaborative agreement under
7Section 65-35 of the Nurse Practice Act, of an advanced
8practice registered nurse certified as a nurse practitioner,
9nurse midwife, or clinical nurse specialist who has been
10granted authority to prescribe by a hospital affiliate in
11accordance with Section 65-45 of the Nurse Practice Act and in
12accordance with Section 303.05 when required by law, or of an
13advanced practice registered nurse certified as a nurse
14practitioner, nurse midwife, or clinical nurse specialist who
15has full practice authority pursuant to Section 65-43 of the
16Nurse Practice Act.
17    (nn-5) "Prescription Information Library" (PIL) means an
18electronic library that contains reported controlled substance
19data.
20    (nn-10) "Prescription Monitoring Program" (PMP) means the
21entity that collects, tracks, and stores reported data on
22controlled substances and select drugs pursuant to Section
23316.
24    (oo) "Production" or "produce" means manufacture,
25planting, cultivating, growing, or harvesting of a controlled
26substance other than methamphetamine.
		SB3221	- 24 -	LRB104 20204 RLC 33655 b
1    (pp) "Registrant" means every person who is required to
2register under Section 302 of this Act.
3    (qq) "Registry number" means the number assigned to each
4person authorized to handle controlled substances under the
5laws of the United States and of this State.
6    (qq-5) "Secretary" means, as the context requires, either
7the Secretary of the Department or the Secretary of the
8Department of Financial and Professional Regulation, and the
9Secretary's designated agents.
10    (rr) "State" includes the State of Illinois and any state,
11district, commonwealth, territory, insular possession thereof,
12and any area subject to the legal authority of the United
13States of America.
14    (rr-5) "Stimulant" means any drug that (i) causes an
15overall excitation of central nervous system functions, (ii)
16causes impaired consciousness and awareness, and (iii) can be
17habit-forming or lead to a substance use disorder, including,
18but not limited to, amphetamines and their analogs,
19methylphenidate and its analogs, cocaine, and phencyclidine
20and its analogs.
21    (rr-10) "Synthetic drug" includes, but is not limited to,
22any synthetic cannabinoids or piperazines or any synthetic
23cathinones as provided for in Schedule I.
24    (ss) "Ultimate user" means a person who lawfully possesses
25a controlled substance for his or her own use or for the use of
26a member of his or her household or for administering to an
		SB3221	- 25 -	LRB104 20204 RLC 33655 b
1animal owned by him or her or by a member of his or her
2household.
3(Source: P.A. 102-389, eff. 1-1-22; 102-538, eff. 8-20-21;
4102-813, eff. 5-13-22; 103-881, eff. 1-1-25.)
5    (720 ILCS 570/204)  (from Ch. 56 1/2, par. 1204)
6    Sec. 204. (a) The controlled substances listed in this
7Section are included in Schedule I.
8    (b) Unless specifically excepted or unless listed in
9another schedule, any of the following opiates, including
10their isomers, esters, ethers, salts, and salts of isomers,
11esters, and ethers, whenever the existence of such isomers,
12esters, ethers and salts is possible within the specific
13chemical designation:
14        (1) Acetylmethadol;
15        (1.1) (Blank); [Acetyl-alpha-methylfentanyl]
16    [(N-[1-(1-methyl-2-phenethyl)-]
17    [4-piperidinyl]-N-phenylacetamide);]
18        (2) Allylprodine;
19        (3) Alphacetylmethadol, except
20    levo-alphacetylmethadol (also known as levo-alpha-
21    acetylmethadol, levomethadyl acetate, or LAAM);
22        (4) Alphameprodine;
23        (5) Alphamethadol;
24        (6) Alpha-methylfentanyl
25    (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
		SB3221	- 26 -	LRB104 20204 RLC 33655 b
1    propionanilide;  1-(1-methyl-2-phenylethyl)-4-(N-
2    propanilido) piperidine;
3        (6.1) (Blank); [Alpha-methylthiofentanyl]
4    [(N-[1-methyl-2-(2-thienyl)ethyl-]
5    [4-piperidinyl]-N-phenylpropanamide);]
6        (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
7        (7.1) PEPAP
8    (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
9        (8) Benzethidine;
10        (9) Betacetylmethadol;
11        (9.1) (Blank); [Beta-hydroxyfentanyl]
12    [(N-[1-(2-hydroxy-2-phenethyl)-]
13    [4-piperidinyl]-N-phenylpropanamide);]
14        (10) Betameprodine;
15        (11) Betamethadol;
16        (12) Betaprodine;
17        (12.1) Brorphine;
18        (13) Clonitazene;
19        (14) Dextromoramide;
20        (15) Diampromide;
21        (16) Diethylthiambutene;
22        (17) Difenoxin;
23        (18) Dimenoxadol;
24        (19) Dimepheptanol;
25        (20) Dimethylthiambutene;
26        (21) Dioxaphetylbutyrate;
		SB3221	- 27 -	LRB104 20204 RLC 33655 b
1        (22) Dipipanone;
2        (23) Ethylmethylthiambutene;
3        (24) Etonitazene;
4        (25) Etoxeridine;
5        (25.1) Flunitazene;
6        (26) Furethidine;
7        (27) Hydroxpethidine;
8        (27.1) Isotonitazene;
9        (28) Ketobemidone;
10        (29) Levomoramide;
11        (30) Levophenacylmorphan;
12        (31) (Blank); [3-Methylfentanyl]
13    [(N-[3-methyl-1-(2-phenylethyl)-]
14    [4-piperidyl]-N-phenylpropanamide);]
15        (31.1) (Blank); [3-Methylthiofentanyl]
16    [(N-[(3-methyl-1-(2-thienyl)ethyl-]
17    [4-piperidinyl]-N-phenylpropanamide);]
18        (31.2) Metonitazene;
19        (32) Morpheridine;
20        (33) Noracymethadol;
21        (34) Norlevorphanol;
22        (35) Normethadone;
23        (36) Norpipanone;
24        (36.1) (Blank); [Para-fluorofentanyl]
25    [(N-(4-fluorophenyl)-N-[1-(2-phenethyl)-]
26    [4-piperidinyl]propanamide);]
		SB3221	- 28 -	LRB104 20204 RLC 33655 b
1        (37) Phenadoxone;
2        (38) Phenampromide;
3        (39) Phenomorphan;
4        (40) Phenoperidine;
5        (41) Piritramide;
6        (42) Proheptazine;
7        (43) Properidine;
8        (44) Propiram;
9        (45) Racemoramide;
10        (45.1) (Blank); [Thiofentanyl]
11    [(N-phenyl-N-[1-(2-thienyl)ethyl-]
12    [4-piperidinyl]-propanamide);]
13        (46) Tilidine;
14        (47) Trimeperidine;
15        (48) (Blank); [Beta-hydroxy-3-methylfentanyl (other ]
16[name:]
17    [N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-]
18    [N-phenylpropanamide);]
19        (49) (Blank); [Furanyl fentanyl (FU-F);]
20        (50) (Blank); [Butyryl fentanyl;]
21        (51) (Blank); [Valeryl fentanyl;]
22        (52) (Blank); [Acetyl fentanyl;]
23        (53) (Blank); [Beta-hydroxy-thiofentanyl;]
24        (54) 3,4-dichloro-N-[2-
25    (dimethylamino)cyclohexyl]-N-
26    methylbenzamide (U-47700); 
		SB3221	- 29 -	LRB104 20204 RLC 33655 b
1        (55) 4-chloro-N-[1-[2-
2    (4-nitrophenyl)ethyl]-2-piperidinylidene]-
3    benzenesulfonamide (W-18); 
4        (56) 4-chloro-N-[1-(2-phenylethyl)
5    -2-piperidinylidene]-benzenesulfonamide (W-15); 
6        (57) (Blank). [acrylfentanyl (acryloylfentanyl).] 
7    (c) Unless specifically excepted or unless listed in
8another schedule, any of the following opium derivatives, its
9salts, isomers and salts of isomers, whenever the existence of
10such salts, isomers and salts of isomers is possible within
11the specific chemical designation:
12        (1) Acetorphine;
13        (2) Acetyldihydrocodeine;
14        (3) Benzylmorphine;
15        (4) Codeine methylbromide;
16        (5) Codeine-N-Oxide;
17        (6) Cyprenorphine;
18        (7) Desomorphine;
19        (8) Diacetyldihydromorphine (Dihydroheroin);
20        (9) Dihydromorphine;
21        (10) Drotebanol;
22        (11) Etorphine (except hydrochloride salt);
23        (12) Heroin;
24        (13) Hydromorphinol;
25        (14) Methyldesorphine;
26        (15) Methyldihydromorphine;
		SB3221	- 30 -	LRB104 20204 RLC 33655 b
1        (16) Morphine methylbromide;
2        (17) Morphine methylsulfonate;
3        (18) Morphine-N-Oxide;
4        (19) Myrophine;
5        (20) Nicocodeine;
6        (21) Nicomorphine;
7        (22) Normorphine;
8        (23) Pholcodine;
9        (24) Thebacon.
10    (d) Unless specifically excepted or unless listed in
11another schedule, any material, compound, mixture, or
12preparation which contains any quantity of the following
13hallucinogenic substances, or which contains any of its salts,
14isomers and salts of isomers, whenever the existence of such
15salts, isomers, and salts of isomers is possible within the
16specific chemical designation (for the purposes of this
17paragraph only, the term "isomer" includes the optical,
18position and geometric isomers):
19        (1) 3,4-methylenedioxyamphetamine
20    (alpha-methyl,3,4-methylenedioxyphenethylamine,
21    methylenedioxyamphetamine, MDA);
22        (1.1) Alpha-ethyltryptamine
23    (some trade or other names: etryptamine;
24    MONASE; alpha-ethyl-1H-indole-3-ethanamine;
25    3-(2-aminobutyl)indole; a-ET; and AET);
26        (2) 3,4-methylenedioxymethamphetamine (MDMA);
		SB3221	- 31 -	LRB104 20204 RLC 33655 b
1        (2.1) 3,4-methylenedioxy-N-ethylamphetamine
2    (also known as: N-ethyl-alpha-methyl-
3    3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
4    and MDEA);
5        (2.2) (Blank); [N-Benzylpiperazine (BZP);]
6        (2.2-1) (Blank); [Trifluoromethylphenylpiperazine ]
7    [(TFMPP);]
8        (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);
9        (4) 3,4,5-trimethoxyamphetamine (TMA);
10        (5) (Blank);
11        (6) Diethyltryptamine (DET);
12        (7) Dimethyltryptamine (DMT);
13        (7.1) 5-Methoxy-diallyltryptamine;
14        (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
15        (9) Ibogaine  (some trade and other names:
16    7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
17    6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
18    indole; Tabernanthe iboga);
19        (10) Lysergic acid diethylamide;
20        (10.1) Salvinorin A;
21        (10.5) Salvia divinorum (meaning all parts of the
22    plant presently classified botanically as Salvia
23    divinorum, whether growing or not, the seeds thereof, any
24    extract from any part of that plant, and every compound,
25    manufacture, salts, isomers, and salts of isomers whenever
26    the existence of such salts, isomers, and salts of isomers
		SB3221	- 32 -	LRB104 20204 RLC 33655 b
1    is possible within the specific chemical designation,
2    derivative, mixture, or preparation of that plant, its
3    seeds or extracts);
4        (11) 3,4,5-trimethoxyphenethylamine (Mescaline);
5        (12) Peyote (meaning all parts of the plant presently
6    classified botanically as Lophophora williamsii Lemaire,
7    whether growing or not, the seeds thereof, any extract
8    from any part of that plant, and every compound,
9    manufacture, salts, derivative, mixture, or preparation of
10    that plant, its seeds or extracts);
11        (13) N-ethyl-3-piperidyl benzilate (JB 318);
12        (14) N-methyl-3-piperidyl benzilate;
13        (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
14    (also known as N-hydroxy-alpha-methyl-
15    3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);
16        (15) Parahexyl; some trade or other names:
17    3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
18    dibenzo (b,d) pyran; Synhexyl;
19        (16) Psilocybin;
20        (17) Psilocyn;
21        (18) Alpha-methyltryptamine (AMT);
22        (19) 2,5-dimethoxyamphetamine
23    (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);
24        (20) 4-bromo-2,5-dimethoxyamphetamine
25    (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
26    4-bromo-2,5-DMA);
		SB3221	- 33 -	LRB104 20204 RLC 33655 b
1        (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
2    Some trade or other names: 2-(4-bromo-
3    2,5-dimethoxyphenyl)-1-aminoethane;
4    alpha-desmethyl DOB, 2CB, Nexus;
5        (21) 4-methoxyamphetamine
6    (4-methoxy-alpha-methylphenethylamine;
7    paramethoxyamphetamine; PMA);
8        (22) (Blank);
9        (23) Ethylamine analog of phencyclidine.
10    Some trade or other names:
11    N-ethyl-1-phenylcyclohexylamine,
12    (1-phenylcyclohexyl) ethylamine,
13    N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;
14        (24) Pyrrolidine analog of phencyclidine. Some trade
15    or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,
16    PHP;
17        (25) 5-methoxy-3,4-methylenedioxy-amphetamine;
18        (26) 2,5-dimethoxy-4-ethylamphetamine
19    (another name: DOET);
20        (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
21    (another name: TCPy);
22        (28) (Blank);
23        (29) Thiophene analog of phencyclidine (some trade
24    or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
25    2-thienyl analog of phencyclidine; TPCP; TCP);
26        (29.1) Benzothiophene analog of phencyclidine. Some
		SB3221	- 34 -	LRB104 20204 RLC 33655 b
1    trade or other names: BTCP or benocyclidine;
2        (29.2) 3-Methoxyphencyclidine (3-MeO-PCP);
3        (30) Bufotenine (some trade or other names:
4    3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
5    3-(2-dimethylaminoethyl)-5-indolol;
6    5-hydroxy-N,N-dimethyltryptamine;
7    N,N-dimethylserotonin; mappine);
8        (31) (Blank);  
9        (32) (Blank);  
10        (33) (Blank);  
11        (34) (Blank); 
12        (34.5) (Blank);  
13        (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-
14    (2-methyloctan-2-yl)-6a,7, 
15    10,10a-tetrahydrobenzo[c]chromen-1-ol
16    Some trade or other names: HU-210; 
17        (35.5)  (6aS,10aS)-9-(hydroxymethyl)-6,6- 
18    dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- 
19    tetrahydrobenzo[c]chromen-1-ol, its isomers,  
20    salts, and salts of isomers; Some trade or other  
21    names: HU-210, Dexanabinol; 
22        (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-
23    6,6-dimethyl-3-(2-methyloctan-2-yl)- 
24    6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
25    Some trade or other names: HU-211;
26        (37) (Blank);
		SB3221	- 35 -	LRB104 20204 RLC 33655 b
1        (38) (Blank);
2        (39) (Blank);
3        (40) (Blank);
4        (41) (Blank);
5        (42) (Blank); [Any compound structurally derived from ]
6    [3-(1-naphthoyl)indole or ]
7    [1H-indol-3-yl-(1-naphthyl)methane by substitution at the ]
8    [nitrogen atom of the indole ring by alkyl, haloalkyl, ]
9    [alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, ]
10    [alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or ]
11    [2-(4-morpholinyl)ethyl whether or not further substituted ]
12    [in the indole ring to any extent, whether or not ]
13    [substituted in the naphthyl ring to any extent. Examples ]
14    [of this structural class include, but are not limited to, ]
15    [JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185;]
16        (43) (Blank); [Any compound structurally derived from ]
17    [3-(1-naphthoyl)pyrrole by substitution at the nitrogen ]
18    [atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, ]
19    [cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl ]
20    [halide, 1-(N-methyl-2-piperidinyl)methyl, or ]
21    [2-(4-morpholinyl)ethyl, whether or not further substituted ]
22    [in the pyrrole ring to any extent, whether or not ]
23    [substituted in the naphthyl ring to any extent. Examples ]
24    [of this structural class include, but are not limited to, ]
25    [JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368;]
26        (44) (Blank); [Any compound structurally derived from ]
		SB3221	- 36 -	LRB104 20204 RLC 33655 b
1    [1-(1-naphthylmethyl)indene by substitution at the ]
2    [3-position of the indene ring by alkyl, haloalkyl, ]
3    [alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, ]
4    [alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or ]
5    [2-(4-morpholinyl)ethyl whether or not further substituted ]
6    [in the indene ring to any extent, whether or not ]
7    [substituted in the naphthyl ring to any extent. Examples ]
8    [of this structural class include, but are not limited to, ]
9    [JWH-176;]
10        (45) (Blank); [Any compound structurally derived from ]
11    [3-phenylacetylindole by substitution at the nitrogen atom ]
12    [of the indole ring with alkyl, haloalkyl, alkenyl, ]
13    [cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl ]
14    [halide, 1-(N-methyl-2-piperidinyl)methyl, or ]
15    [2-(4-morpholinyl)ethyl, whether or not further substituted ]
16    [in the indole ring to any extent, whether or not ]
17    [substituted in the phenyl ring to any extent. Examples of ]
18    [this structural class include, but are not limited to, ]
19    [JWH-167, JWH-250, JWH-251, and RCS-8;]
20        (46) (Blank); [Any compound structurally derived from ]
21    [2-(3-hydroxycyclohexyl)phenol by substitution at the ]
22    [5-position of the phenolic ring by alkyl, haloalkyl, ]
23    [alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, ]
24    [alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or ]
25    [2-(4-morpholinyl)ethyl, whether or not substituted in the ]
26    [cyclohexyl ring to any extent. Examples of this structural ]
		SB3221	- 37 -	LRB104 20204 RLC 33655 b
1    [class include, but are not limited to, CP 47, 497 and its ]
2    [C8 homologue (cannabicyclohexanol);]
3        (46.1) (Blank); [Any compound structurally derived from ]
4    [3-(benzoyl) indole with substitution at the nitrogen atom ]
5    [of the indole ring by an alkyl, haloalkyl, alkenyl, ]
6    [cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl ]
7    [halide, 1-(N-methyl-2-piperidinyl)methyl, or ]
8    [2-(4-morpholinyl)ethyl group whether or not further ]
9    [substituted in the indole ring to any extent and whether ]
10    [or not substituted in the phenyl ring to any extent. ]
11    [Examples of this structural class include, but are not ]
12    [limited to, AM-630, AM-2233, AM-694, Pravadoline (WIN ]
13    [48,098), and RCS-4;]
14        (47) (Blank);
15        (48) (Blank);
16        (49) (Blank);
17        (50) (Blank);
18        (51) (Blank);
19        (52) (Blank);
20        (53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine.
21    Some trade or other names: 2C-T-7;
22        (53.1) 4-ethyl-2,5-dimethoxyphenethylamine. Some
23    trade or other names: 2C-E;
24        (53.2) 2,5-dimethoxy-4-methylphenethylamine. Some
25    trade or other names: 2C-D;
26        (53.3) 4-chloro-2,5-dimethoxyphenethylamine. Some
		SB3221	- 38 -	LRB104 20204 RLC 33655 b
1    trade or other names: 2C-C;
2        (53.4) 4-iodo-2,5-dimethoxyphenethylamine. Some trade
3    or other names: 2C-I;
4        (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine. Some
5    trade or other names: 2C-T-2;
6        (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine.
7    Some trade or other names: 2C-T-4;
8        (53.7) 2,5-dimethoxyphenethylamine. Some trade or
9    other names: 2C-H;
10        (53.8) 2,5-dimethoxy-4-nitrophenethylamine. Some
11    trade or other names: 2C-N;
12        (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine. Some
13    trade or other names: 2C-P;
14        (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine.
15    Some trade or other names: 2C-G;
16        (53.11) The N-(2-methoxybenzyl) derivative of any 2C
17    phenethylamine referred to in subparagraphs (20.1), (53),
18    (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7),
19    (53.8), (53.9), and (53.10) including, but not limited to,
20    25I-NBOMe and 25C-NBOMe;
21        (54) 5-Methoxy-N,N-diisopropyltryptamine;
22        (55) (Blank);
23        (56) (Blank);
24        (57) (Blank);
25        (58) (Blank);
26        (59) (Blank); [3-cyclopropoylindole with substitution ]
		SB3221	- 39 -	LRB104 20204 RLC 33655 b
1    [at the nitrogen atom of the indole ring by alkyl, ]
2    [haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, ]
3    [aryl halide, alkyl aryl halide, ]
4    [1-(N-methyl-2-piperidinyl)methyl, or ]
5    [2-(4-morpholinyl)ethyl, whether or not further substituted ]
6    [on the indole ring to any extent, whether or not ]
7    [substituted on the cyclopropyl ring to any extent: ]
8    [including, but not limited to, XLR11, UR144, FUB-144;]
9        (60) (Blank); [3-adamantoylindole with substitution at ]
10    [the nitrogen atom of the indole ring by alkyl, haloalkyl, ]
11    [alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, ]
12    [alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or ]
13    [2-(4-morpholinyl)ethyl, whether or not further substituted ]
14    [on the indole ring to any extent, whether or not ]
15    [substituted on the adamantyl ring to any extent: ]
16    [including, but not limited to, AB-001;]
17        (61) (Blank); [N-(adamantyl)-indole-3-carboxamide with ]
18    [substitution at the nitrogen atom of the indole ring by ]
19    [alkyl, haloalkyl, alkenyl, cycloalkylmethyl, ]
20    [cycloalkylethyl, aryl halide, alkyl aryl halide, ]
21    [1-(N-methyl-2-piperidinyl)methyl, or ]
22    [2-(4-morpholinyl)ethyl, whether or not further substituted ]
23    [on the indole ring to any extent, whether or not ]
24    [substituted on the adamantyl ring to any extent: ]
25    [including, but not limited to, APICA/2NE-1, STS-135;]
26        (62) (Blank); [N-(adamantyl)-indazole-3-carboxamide ]
		SB3221	- 40 -	LRB104 20204 RLC 33655 b
1    [with substitution at a nitrogen atom of the indazole ring ]
2    [by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, ]
3    [cycloalkylethyl, aryl halide, alkyl aryl halide, ]
4    [1-(N-methyl-2-piperidinyl)methyl, or ]
5    [2-(4-morpholinyl)ethyl, whether or not further substituted ]
6    [on the indazole ring to any extent, whether or not ]
7    [substituted on the adamantyl ring to any extent: ]
8    [including, but not limited to, AKB48, 5F-AKB48;]
9        (63) (Blank); [1H-indole-3-carboxylic acid ]
10    [8-quinolinyl ester with substitution at the nitrogen atom ]
11    [of the indole ring by alkyl, haloalkyl, alkenyl, ]
12    [cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl ]
13    [halide, 1-(N-methyl-2-piperidinyl)methyl, or ]
14    [2-(4-morpholinyl)ethyl, whether or not further substituted ]
15    [on the indole ring to any extent, whether or not ]
16    [substituted on the quinoline ring to any extent: ]
17    [including, but not limited to, PB22, 5F-PB22, FUB-PB-22;]
18        (64) (Blank); [3-(1-naphthoyl)indazole with ]
19    [substitution at the nitrogen atom of the indazole ring by ]
20    [alkyl, haloalkyl, alkenyl, cycloalkylmethyl, ]
21    [cycloalkylethyl, aryl halide, alkyl aryl halide, ]
22    [1-(N-methyl-2-piperidinyl)methyl, or ]
23    [2-(4-morpholinyl)ethyl, whether or not further substituted ]
24    [on the indazole ring to any extent, whether or not ]
25    [substituted on the naphthyl ring to any extent: including, ]
26    [but not limited to, THJ-018, THJ-2201;]
		SB3221	- 41 -	LRB104 20204 RLC 33655 b
1        (65) (Blank); [2-(1-naphthoyl)benzimidazole with ]
2    [substitution at the nitrogen atom of the benzimidazole ]
3    [ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, ]
4    [cycloalkylethyl, aryl halide, alkyl aryl halide, ]
5    [1-(N-methyl-2-piperidinyl)methyl, or ]
6    [2-(4-morpholinyl)ethyl, whether or not further substituted ]
7    [on the benzimidazole ring to any extent, whether or not ]
8    [substituted on the naphthyl ring to any extent: including, ]
9    [but not limited to, FUBIMINA;]
10        (66) (Blank); [N-(1-amino-3-methyl-1-oxobutan-2-yl)- ]
11    [1H-indazole-3-carboxamide with substitution on the ]
12    [nitrogen atom of the indazole ring by alkyl, haloalkyl, ]
13    [alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, ]
14    [alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or ]
15    [2-(4-morpholinyl)ethyl, whether or not further substituted ]
16    [on the indazole ring to any extent: including, but not ]
17    [limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA;]
18        (67) (Blank); [N-(1-amino-3,3-dimethyl-1-oxobutan- ]
19    [2-yl)-1H-indazole-3-carboxamide with substitution on the ]
20    [nitrogen atom of the indazole ring by alkyl, haloalkyl, ]
21    [alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, ]
22    [alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or ]
23    [2-(4-morpholinyl)ethyl, whether or not further substituted ]
24    [on the indazole ring to any extent: including, but not ]
25    [limited to, ADB-PINACA, ADB-FUBINACA;]
26        (68) (Blank); [N-(1-amino-3,3-dimethyl-1-oxobutan- ]
		SB3221	- 42 -	LRB104 20204 RLC 33655 b
1    [2-yl)-1H-indole-3-carboxamide with substitution on the ]
2    [nitrogen atom of the indole ring by alkyl, haloalkyl, ]
3    [alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, ]
4    [alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or ]
5    [2-(4-morpholinyl)ethyl, whether or not further substituted ]
6    [on the indole ring to any extent: including, but not ]
7    [limited to, ADBICA, 5F-ADBICA;]
8        (69) (Blank); [N-(1-amino-3-methyl-1-oxobutan-2 -]
9    [yl)-1H-indole-3-carboxamide with substitution on the ]
10    [nitrogen atom of the indole ring by alkyl, haloalkyl, ]
11    [alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, ]
12    [alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or ]
13    [2-(4-morpholinyl)ethyl, whether or not further substituted ]
14    [on the indole ring to any extent: including, but not ]
15    [limited to, ABICA, 5F-ABICA;]
16        (70) (Blank); [Methyl 2-(1H-indazole-3-carboxamido)-3- ]
17    [methylbutanoate with substitution on the nitrogen atom of ]
18    [the indazole ring by alkyl, haloalkyl, alkenyl, ]
19    [cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl ]
20    [halide, 1-(N-methyl-2-piperidinyl)methyl, or ]
21    [2-(4-morpholinyl)ethyl, whether or not further substituted ]
22    [on the indazole ring to any extent: including, but not ]
23    [limited to, AMB, 5F-AMB;]
24        (71) (Blank); [Methyl 2-(1H-indazole-3-carboxamido)- ]
25    [3,3-dimethylbutanoate with substitution on the nitrogen ]
26    [atom of the indazole ring by alkyl, haloalkyl, alkenyl, ]
		SB3221	- 43 -	LRB104 20204 RLC 33655 b
1    [cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl ]
2    [halide, 1-(N-methyl-2-piperidinyl)methyl, or ]
3    [2-(4-morpholinyl)ethyl, whether or not further substituted ]
4    [on the indazole ring to any extent: including, but not ]
5    [limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA;]
6        (72) (Blank); [Methyl 2-(1H-indole-3-carboxamido)-3- ]
7    [methylbutanoate with substitution on the nitrogen atom of ]
8    [the indole ring by alkyl, haloalkyl, alkenyl, ]
9    [cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl ]
10    [halide, 1-(N-methyl-2-piperidinyl)methyl, or ]
11    [2-(4-morpholinyl)ethyl, whether or not further substituted ]
12    [on the indazole ring to any extent: including, but not ]
13    [limited to, MMB018, MMB2201, and AMB-CHMICA;]
14        (73) (Blank); [Methyl 2-(1H-indole-3-carboxamido)-3,3- ]
15    [dimethylbutanoate with substitution on the nitrogen atom ]
16    [of the indole ring by alkyl, haloalkyl, alkenyl, ]
17    [cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl ]
18    [halide, 1-(N-methyl-2-piperidinyl)methyl, or ]
19    [2-(4-morpholinyl)ethyl, whether or not further substituted ]
20    [on the indazole ring to any extent: including, but not ]
21    [limited to, MDMB-CHMICA;]
22        (74) (Blank); [N-(1-Amino-1-oxo-3-phenylpropan- ]
23    [2-yl)-1H-indazole-3-carboxamide with substitution on the ]
24    [nitrogen atom of the indazole ring by alkyl, haloalkyl, ]
25    [alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, ]
26    [alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or ]
		SB3221	- 44 -	LRB104 20204 RLC 33655 b
1    [2-(4-morpholinyl)ethyl, whether or not further substituted ]
2    [on the indazole ring to any ][    ][extent: including, but not ]
3    [limited to, APP-CHMINACA, 5-fluoro-APP-PINACA;]
4        (75) (Blank); [N-(1-Amino-1-oxo-3-phenylpropan- ]
5    [2-yl)-1H-indole-3-carboxamide with substitution on the ]
6    [nitrogen atom of the indole ring by alkyl, haloalkyl, ]
7    [alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, ]
8    [alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or ]
9    [2-(4-morpholinyl)ethyl, whether or not further substituted ]
10    [on the indazole ring to any extent: including, but not ]
11    [limited to, APP-PICA and 5-fluoro-APP-PICA;]
12        (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name
13    4-AcO-DMT;
14        (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade
15    name 5-MeO-MIPT;
16        (78) 4-hydroxy Diethyltryptamine (4-HO-DET);
17        (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);
18        (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
19        (81) 4-hydroxy-N-methyl-N-isopropyltryptamine
20    (4-HO-MiPT);
21        (82) (Blank); [Fluorophenylpiperazine;]
22        (83) Methoxetamine;
23        (84) 1-(Ethylamino)-2-phenylpropan-2-one (iso-
24    ethcathinone).
25    (e) Unless specifically excepted or unless listed in
26another schedule, any material, compound, mixture, or
		SB3221	- 45 -	LRB104 20204 RLC 33655 b
1preparation which contains any quantity of the following
2substances having a depressant effect on the central nervous
3system, including its salts, isomers, and salts of isomers
4whenever the existence of such salts, isomers, and salts of
5isomers is possible within the specific chemical designation:
6        (1) mecloqualone;
7        (2) methaqualone; and
8        (3) gamma hydroxybutyric acid.
9    (f) Unless specifically excepted or unless listed in
10another schedule, any material, compound, mixture, or
11preparation which contains any quantity of the following
12substances having a stimulant effect on the central nervous
13system, including its salts, isomers, and salts of isomers:
14        (1) Fenethylline;
15        (2) N-ethylamphetamine;
16        (3) Aminorex (some other names:
17    2-amino-5-phenyl-2-oxazoline; aminoxaphen;
18    4-5-dihydro-5-phenyl-2-oxazolamine) and its
19    salts, optical isomers, and salts of optical isomers;
20        (4) Methcathinone (some other names:
21    2-methylamino-1-phenylpropan-1-one;
22    Ephedrone; 2-(methylamino)-propiophenone;
23    alpha-(methylamino)propiophenone; N-methylcathinone;
24    methycathinone; Monomethylpropion; UR 1431) and its
25    salts, optical isomers, and salts of optical isomers;
26        (5) Cathinone (some trade or other names:
		SB3221	- 46 -	LRB104 20204 RLC 33655 b
1    2-aminopropiophenone; alpha-aminopropiophenone;
2    2-amino-1-phenyl-propanone; norephedrone);
3        (6) N,N-dimethylamphetamine (also known as:
4    N,N-alpha-trimethyl-benzeneethanamine;
5    N,N-alpha-trimethylphenethylamine);
6        (7) (+ or -) cis-4-methylaminorex  ((+ or -) cis-
7    4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);
8        (8) 3,4-Methylenedioxypyrovalerone (MDPV);
9        (9) Halogenated amphetamines and
10    methamphetamines - any compound derived from either
11    amphetamine or methamphetamine through the substitution
12    of a halogen on the phenyl ring, including, but not
13    limited to, 2-fluoroamphetamine, 3-
14    fluoroamphetamine and 4-fluoroamphetamine; 
15        (10) Aminopropylbenzofuran (APB):
16    including 4-(2-Aminopropyl) benzofuran, 5-
17    (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
18    benzofuran, and 7-(2-Aminopropyl) benzofuran; 
19        (11) Aminopropyldihydrobenzofuran (APDB):
20    including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
21    5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
22    6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
23    and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran; 
24        (12) Methylaminopropylbenzofuran
25    (MAPB): including 4-(2-methylaminopropyl)
26    benzofuran, 5-(2-methylaminopropyl)benzofuran,
		SB3221	- 47 -	LRB104 20204 RLC 33655 b
1    6-(2-methylaminopropyl)benzofuran
2    and 7-(2-methylaminopropyl)benzofuran; [.] 
3        (13) Methylaminopropyldihydrobenzofuran
4    (MAPDB): including 1-(2,3-dihydrobenzofuran-5-yl)-
5    N-methylpropan-2-amine.
6    (g) Temporary listing of substances subject to emergency
7scheduling. Any material, compound, mixture, or preparation
8that contains any quantity of the following substances:
9        (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
10    (benzylfentanyl), its optical isomers, isomers, salts, and
11    salts of isomers;
12        (2) N-[1(2-thienyl) methyl-4-piperidyl]-N-
13    phenylpropanamide (thenylfentanyl), its optical isomers,
14    salts, and salts of isomers.
15    (h) Synthetic cathinones. Unless specifically excepted,
16any chemical compound which is not approved by the United
17States Food and Drug Administration or, if approved, is not
18dispensed or possessed in accordance with State or federal
19law, not including bupropion, structurally derived from
202-aminopropan-1-one by substitution at the 1-position with
21either phenyl, naphthyl, or thiophene ring systems, whether or
22not the compound is further modified in one or more of the
23following ways:
24        (1) by substitution in the ring system to any extent
25    with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or
26    halide substituents, whether or not further substituted in
		SB3221	- 48 -	LRB104 20204 RLC 33655 b
1    the ring system by one or more other univalent
2    substituents. Examples of this class include, but are not
3    limited to, 3,4-Methylenedioxycathinone (bk-MDA);
4        (2) by substitution at the 3-position with an acyclic
5    alkyl substituent. Examples of this class include, but are
6    not limited to, 2-methylamino-1-phenylbutan-1-one
7    (buphedrone); or
8        (3) by substitution at the 2-amino nitrogen atom with
9    alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by
10    inclusion of the 2-amino nitrogen atom in a cyclic
11    structure. Examples of this class include, but are not
12    limited to, Dimethylcathinone, Ethcathinone, and
13    a-Pyrrolidinopropiophenone (a-PPP); or
14    Any other synthetic cathinone which is not approved by the
15United States Food and Drug Administration or, if approved, is
16not dispensed or possessed in accordance with State or federal
17law.
18    (i) Synthetic cannabinoids or piperazines. Any synthetic
19cannabinoid or piperazine which is not approved by the United
20States Food and Drug Administration or, if approved, which is
21not dispensed or possessed in accordance with State and
22federal law.
23        (1) As used in this Section, "synthetic cannabinoid" 
24    includes, but is not limited to, any compound, as 
25    identified in a report from an accredited forensic 
26    laboratory, that is structurally derived from any one or 
		SB3221	- 49 -	LRB104 20204 RLC 33655 b
1    more of the following compounds:
2            (A) Any compound structurally derived from 
3        3-(1-naphthoyl)indole or 
4        1H-indol-3-yl-(1-naphthyl)methane by substitution at 
5        the nitrogen atom of the indole ring by alkyl, 
6        haloalkyl, alkenyl, cycloalkylmethyl, 
7        cycloalkylethyl, aryl halide, alkyl aryl halide, 
8        1-(N-methyl-2-piperidinyl)methyl, or 
9        2-(4-morpholinyl)ethyl whether or not further 
10        substituted in the indole ring to any extent, whether 
11        or not substituted in the naphthyl ring to any extent. 
12        Examples of this structural class include, but are not 
13        limited to, JWH-018, AM-2201, JWH-175, JWH-184, and 
14        JWH-185;
15            (B) 3-(1-naphthoyl)pyrrole by substitution at the 
16        nitrogen atom of the pyrrole ring by alkyl, haloalkyl, 
17        alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl 
18        halide, alkyl aryl halide, 
19        1-(N-methyl-2-piperidinyl)methyl, or 
20        2-(4-morpholinyl)ethyl, whether or not further 
21        substituted in the pyrrole ring to any extent, whether 
22        or not substituted in the naphthyl ring to any extent. 
23        Examples of this structural class include, but are not 
24        limited to, JWH-030, JWH-145, JWH-146, JWH-307, and 
25        JWH-368;
26            (C) 1-(1-naphthylmethyl)indene by substitution at 
		SB3221	- 50 -	LRB104 20204 RLC 33655 b
1        the 3-position of the indene ring by alkyl, haloalkyl, 
2        alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl 
3        halide, alkyl aryl halide, 
4        1-(N-methyl-2-piperidinyl)methyl, or 
5        2-(4-morpholinyl)ethyl whether or not further 
6        substituted in the indene ring to any extent, whether 
7        or not substituted in the naphthyl ring to any extent. 
8        Examples of this structural class include, but are not 
9        limited to, JWH-176;
10            (D) 3-phenylacetylindole by substitution at the 
11        nitrogen atom of the indole ring with alkyl, 
12        haloalkyl, alkenyl, cycloalkylmethyl, 
13        cycloalkylethyl, aryl halide, alkyl aryl halide, 
14        1-(N-methyl-2-piperidinyl)methyl, or 
15        2-(4-morpholinyl)ethyl, whether or not further 
16        substituted in the indole ring to any extent, whether 
17        or not substituted in the phenyl ring to any extent. 
18        Examples of this structural class include, but are not 
19        limited to, JWH-167, JWH-250, JWH-251, and RCS-8;
20            (E) 2-(3-hydroxycyclohexyl)phenol by substitution 
21        at the 5-position of the phenolic ring by alkyl, 
22        haloalkyl, alkenyl, cycloalkylmethyl, 
23        cycloalkylethyl, aryl halide, alkyl aryl halide, 
24        1-(N-methyl-2-piperidinyl)methyl, or 
25        2-(4-morpholinyl)ethyl, whether or not substituted in 
26        the cyclohexyl ring to any extent. Examples of this 
		SB3221	- 51 -	LRB104 20204 RLC 33655 b
1        structural class include, but are not limited to, CP 
2        47, 497 and its C8 homologue (cannabicyclohexanol);
3            (F) 3-(benzoyl) indole with substitution at the 
4        nitrogen atom of the indole ring by an alkyl, 
5        haloalkyl, alkenyl, cycloalkylmethyl, 
6        cycloalkylethyl, aryl halide, alkyl aryl halide, 
7        1-(N-methyl-2-piperidinyl)methyl, or 
8        2-(4-morpholinyl)ethyl group whether or not further 
9        substituted in the indole ring to any extent and 
10        whether or not substituted in the phenyl ring to any 
11        extent. Examples of this structural class include, but 
12        are not limited to, AM-630, AM-2233, AM-694, 
13        Pravadoline (WIN 48,098), and RCS-4;
14            (G) 3-cyclopropoylindole with substitution at the 
15        nitrogen atom of the indole ring by alkyl, haloalkyl, 
16        alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl 
17        halide, alkyl aryl halide, 
18        1-(N-methyl-2-piperidinyl)methyl, or 
19        2-(4-morpholinyl)ethyl, whether or not further 
20        substituted on the indole ring to any extent, whether 
21        or not substituted on the cyclopropyl ring to any 
22        extent, including, but not limited to, XLR11, UR144, 
23        FUB-144;
24            (H) 3-adamantoylindole with substitution at the 
25        nitrogen atom of the indole ring by alkyl, haloalkyl, 
26        alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl 
		SB3221	- 52 -	LRB104 20204 RLC 33655 b
1        halide, alkyl aryl halide, 
2        1-(N-methyl-2-piperidinyl)methyl, or 
3        2-(4-morpholinyl)ethyl, whether or not further 
4        substituted on the indole ring to any extent, whether 
5        or not substituted on the adamantyl ring to any 
6        extent, including, but not limited to, AB-001;
7            (I) N-(adamantyl)-indole-3-carboxamide with 
8        substitution at the nitrogen atom of the indole ring 
9        by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, 
10        cycloalkylethyl, aryl halide, alkyl aryl halide, 
11        1-(N-methyl-2-piperidinyl)methyl, or 
12        2-(4-morpholinyl)ethyl, whether or not further 
13        substituted on the indole ring to any extent, whether 
14        or not substituted on the adamantyl ring to any 
15        extent, including, but not limited to, APICA/2NE-1, 
16        STS-135;
17            (J) N-(adamantyl)-indazole-3-carboxamide with 
18        substitution at a nitrogen atom of the indazole ring 
19        by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, 
20        cycloalkylethyl, aryl halide, alkyl aryl halide, 
21        1-(N-methyl-2-piperidinyl)methyl, or 
22        2-(4-morpholinyl)ethyl, whether or not further 
23        substituted on the indazole ring to any extent, 
24        whether or not substituted on the adamantyl ring to 
25        any extent, including, but not limited to, AKB48, 
26        5F-AKB48;
		SB3221	- 53 -	LRB104 20204 RLC 33655 b
1            (K) 1H-indole-3-carboxylic acid 8-quinolinyl ester 
2        with substitution at the nitrogen atom of the indole 
3        ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, 
4        cycloalkylethyl, aryl halide, alkyl aryl halide, 
5        1-(N-methyl-2-piperidinyl)methyl, or 
6        2-(4-morpholinyl)ethyl, whether or not further 
7        substituted on the indole ring to any extent, whether 
8        or not substituted on the quinoline ring to any 
9        extent, including, but not limited to, PB22, 5F-PB22, 
10        FUB-PB-22;
11            (L) 3-(1-naphthoyl)indazole with substitution at 
12        the nitrogen atom of the indazole ring by alkyl, 
13        haloalkyl, alkenyl, cycloalkylmethyl, 
14        cycloalkylethyl, aryl halide, alkyl aryl halide, 
15        1-(N-methyl-2-piperidinyl)methyl, or 
16        2-(4-morpholinyl)ethyl, whether or not further 
17        substituted on the indazole ring to any extent, 
18        whether or not substituted on the naphthyl ring to any 
19        extent, including, but not limited to, THJ-018, 
20        THJ-2201;
21            (M) 2-(1-naphthoyl)benzimidazole with 
22        substitution at the nitrogen atom of the benzimidazole 
23        ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, 
24        cycloalkylethyl, aryl halide, alkyl aryl halide, 
25        1-(N-methyl-2-piperidinyl)methyl, or 
26        2-(4-morpholinyl)ethyl, whether or not further 
		SB3221	- 54 -	LRB104 20204 RLC 33655 b
1        substituted on the benzimidazole ring to any extent, 
2        whether or not substituted on the naphthyl ring to any 
3        extent, including, but not limited to, FUBIMINA;
4            (N) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H- 
5        indazole-3-carboxamide with substitution on the 
6        nitrogen atom of the indazole ring by alkyl, 
7        haloalkyl, alkenyl, cycloalkylmethyl, 
8        cycloalkylethyl, aryl halide, alkyl aryl halide, 
9        1-(N-methyl-2-piperidinyl)methyl, or 
10        2-(4-morpholinyl)ethyl, whether or not further 
11        substituted on the indazole ring to any extent, 
12        including, but not limited to, AB-PINACA, AB-FUBINACA, 
13        AB-CHMINACA;
14            (O) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)- 
15        1H-indazole-3-carboxamide with substitution on the 
16        nitrogen atom of the indazole ring by alkyl, 
17        haloalkyl, alkenyl, cycloalkylmethyl, 
18        cycloalkylethyl, aryl halide, alkyl aryl halide, 
19        1-(N-methyl-2-piperidinyl)methyl, or 
20        2-(4-morpholinyl)ethyl, whether or not further 
21        substituted on the indazole ring to any extent, 
22        including, but not limited to, ADB-PINACA, 
23        ADB-FUBINACA;
24            (P) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)- 
25        1H-indole-3-carboxamide with substitution on the 
26        nitrogen atom of the indole ring by alkyl, haloalkyl, 
		SB3221	- 55 -	LRB104 20204 RLC 33655 b
1        alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl 
2        halide, alkyl aryl halide, 
3        1-(N-methyl-2-piperidinyl)methyl, or 
4        2-(4-morpholinyl)ethyl, whether or not further 
5        substituted on the indole ring to any extent, 
6        including, but not limited to, ADBICA, 5F-ADBICA;
7            (Q) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H- 
8        indole-3-carboxamide with substitution on the nitrogen 
9        atom of the indole ring by alkyl, haloalkyl, alkenyl, 
10        cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl 
11        aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 
12        2-(4-morpholinyl)ethyl, whether or not further 
13        substituted on the indole ring to any extent, 
14        including, but not limited to, ABICA, 5F-ABICA;
15            (R) Methyl 2-(1H-indazole-3-carboxamido)- 
16        3-methylbutanoate with substitution on the nitrogen 
17        atom of the indazole ring by alkyl, haloalkyl, 
18        alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl 
19        halide, alkyl aryl halide, 
20        1-(N-methyl-2-piperidinyl)methyl, or 
21        2-(4-morpholinyl)ethyl, whether or not further 
22        substituted on the indazole ring to any extent, 
23        including, but not limited to, AMB, 5F-AMB;
24            (S) Methyl 2-(1H-indazole-3-carboxamido)- 
25        3,3-dimethylbutanoate with substitution on the 
26        nitrogen atom of the indazole ring by alkyl, 
		SB3221	- 56 -	LRB104 20204 RLC 33655 b
1        haloalkyl, alkenyl, cycloalkylmethyl, 
2        cycloalkylethyl, aryl halide, alkyl aryl halide, 
3        1-(N-methyl-2-piperidinyl)methyl, or 
4        2-(4-morpholinyl)ethyl, whether or not further 
5        substituted on the indazole ring to any extent, 
6        including, but not limited to, 5-fluoro-MDMB-PINACA, 
7        MDMB-FUBINACA;
8            (T) Methyl 2-(1H-indole-3-carboxamido)-3- 
9        methylbutanoate with substitution on the nitrogen atom 
10        of the indole ring by alkyl, haloalkyl, alkenyl, 
11        cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl 
12        aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 
13        2-(4-morpholinyl)ethyl, whether or not further 
14        substituted on the indole ring to any extent, 
15        including, but not limited to, MMB018, MMB2201, and 
16        AMB-CHMICA;
17            (U) Methyl 2-(1H-indole-3-carboxamido)-3,3- 
18        dimethylbutanoate with substitution on the nitrogen 
19        atom of the indole ring by alkyl, haloalkyl, alkenyl, 
20        cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl 
21        aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 
22        2-(4-morpholinyl)ethyl, whether or not further 
23        substituted on the indazole indole ring to any extent, 
24        including, but not limited to, MDMB-CHMICA;
25            (V) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H- 
26        indazole-3-carboxamide with substitution on the 
		SB3221	- 57 -	LRB104 20204 RLC 33655 b
1        nitrogen atom of the indazole ring by alkyl, 
2        haloalkyl, alkenyl, cycloalkylmethyl, 
3        cycloalkylethyl, aryl halide, alkyl aryl halide, 
4        1-(N-methyl-2-piperidinyl)methyl, or 
5        2-(4-morpholinyl)ethyl, whether or not further 
6        substituted on the indazole ring to any extent, 
7        including, but not limited to, APP-CHMINACA, 
8        5-fluoro-APP-PINACA;
9            (W) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)- 
10        1H-indole-3-carboxamide with substitution on the 
11        nitrogen atom of the indole ring by alkyl, haloalkyl, 
12        alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl 
13        halide, alkyl aryl halide, 
14        1-(N-methyl-2-piperidinyl)methyl, or 
15        2-(4-morpholinyl)ethyl, whether or not further 
16        substituted on the indole ring to any extent, 
17        including, but not limited to, APP-PICA and 
18        5-fluoro-APP-PICA;
19            (X) 1H-indazole-3-carboxylic acid 8-quinolinyl 
20        ester with substitution at the nitrogen atom of the 
21        indazole ring by alkyl, haloalkyl, alkenyl, 
22        cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl 
23        aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 
24        2-(4-morpholinyl)ethyl, whether or not further 
25        substituted on the inazdole ring to any extent, 
26        whether or not substituted on the quinoline ring to 
		SB3221	- 58 -	LRB104 20204 RLC 33655 b
1        any extent, including, but not limited to, SDB-005, 
2        5-F-SDB-005;
3        (2) As used in this Section, "synthetic piperazine" 
4    includes, but is not limited to, any of the following 
5    compounds and their positional isomers:
6            (A) N-Benzylpiperazine (BZP);
7            (B) Trifluoromethylphenylpiperazine (TFMPP);
8            (C) Fluorophenylpiperazine;
9            (D) Chlorophenylpiperazine.
10    (j) Unless specifically excepted or listed in another
11schedule, any chemical compound which is not approved by the
12United States Food and Drug Administration or, if approved, is
13not dispensed or possessed in accordance with State or federal
14law, and is derived from the following structural classes and
15their salts:
16        (1) Benzodiazepine class: A fused 1,4-diazepine and
17    benzene ring structure with a phenyl connected to the
18    1,4-diazepine ring, with any substitution(s) or
19    replacement(s) on the 1,4-diazepine or benzene ring, any
20    substitution(s) on the phenyl ring, or any combination
21    thereof. Examples of this class include but are not
22    limited to: Clonazolam, Flualprazolam; or
23        (2) Thienodiazepine class: A fused 1,4-diazepine and
24    thiophene ring structure with a phenyl connected to the
25    1,4-diazepine ring, with any substitution(s) or
26    replacement(s) on the 1,4-diazepine or thiophene ring, any
		SB3221	- 59 -	LRB104 20204 RLC 33655 b
1    substitution(s) on the phenyl ring, or any combination
2    thereof. Examples of this class include but are not
3    limited to: Etizolam.
4    (k) Fentanyl-related substances.
5        (1) As used in this Section, "fentanyl-related 
6    substance" means any compound, as identified in a report 
7    from an accredited forensic laboratory, unless 
8    specifically excepted or listed under another schedule, 
9    that is not approved by the United States Food and Drug 
10    Administration or, if approved, is not dispensed or 
11    possessed in accordance with State or federal law and that 
12    is structurally derived from fentanyl 
13    (N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- 
14    propanamide) by one or more of the following 
15    modifications:
16            (A) replacement of the phenyl portion of the 
17        phenethyl group by any monocycle, whether or not 
18        further substituted in or on the monocycle;
19            (B) substitution in or on the phenethyl group with 
20        alkyl, alkenyl, alkoxyl, hydroxyl, halo, haloalkyl, 
21        amino, or nitro groups;
22            (C) substitution in or on the piperidine ring with 
23        alkyl, alkenyl, alkoxyl, ester, ether, hydroxyl, halo, 
24        haloalkyl, amino, or nitro groups;
25            (D) replacement of the aniline ring with any 
26        aromatic monocycle whether or not further substituted 
		SB3221	- 60 -	LRB104 20204 RLC 33655 b
1        in or on the aromatic monocycle; or
2            (E) replacement of the N-propionyl group by 
3        another acyl group.
4        (2) "Fentanyl-related substance" includes, but is not 
5    limited to, the following substances:
6            (A) Acetyl-alpha-methylfentanyl;
7            (B) Alpha-methylfentanyl (N-(1-alpha-methyl-beta- 
8        phenyl)ethyl-4-piperidyl) propionanilide; 
9        1-(1-methyl-2-phenylethyl)-4-(N-propanilido) 
10        piperidine;
11            (C) Alpha-methylthiofentanyl (N-[1-methyl-2-(2- 
12        thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
13            (D) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2- 
14        phenethyl)-4-piperidinyl]-N-phenylpropanamide
15            (E) 3-Methylfentanyl (N-[3-methyl-1-(2- 
16        phenylethyl)-4-piperidyl]-N-phenylpropanamide);
17            (F) 3-Methylthiofentanyl (N-[(3-methyl-1- 
18        (2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
19            (G) Para-fluorofentanyl (N-(4-fluorophenyl)- 
20        N-[1-(2-phenethyl)-4-piperidinyl]propanamide);
21            (H) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl- 
22        4-piperidinyl]-propanamide);
23            (I) Beta-hydroxy-3-methylfentanyl (other name: 
24        N-[1-(2-hydroxy-2-phenethyl)-3-methyl- 
25        4-piperidinyl]-N-phenylpropanamide);
26            (J) Furanyl fentanyl (FU-F);
		SB3221	- 61 -	LRB104 20204 RLC 33655 b
1            (K) Butyryl fentanyl;
2            (L) Valeryl fentanyl;
3            (M) Acetyl fentanyl;
4            (N) Beta-hydroxy-thiofentanyl;
5            (O) Acrylfentanyl (acryloylfentanyl);
6            (P) Cyclopropyl fentanyl;
7            (Q) Crotonyl fentanyl;
8            (R) Methoxyacetyl fentanyl;
9            (S) Pentanoyl fentanyl;
10            (T) Cyclopentyl fentanyl;
11            (U) Isobutyryl fentanyl;
12            (V) Benzodioxolefentanyl;
13            (W) Tetrahydrofuran fentanyl.
14(Source: P.A. 103-245, eff. 1-1-24.)
15    (720 ILCS 570/206)  (from Ch. 56 1/2, par. 1206)
16    Sec. 206. (a) The controlled substances listed in this
17Section are included in Schedule II.
18    (b) Unless specifically excepted or unless listed in
19another schedule, any of the following substances whether
20produced directly or indirectly by extraction from substances
21of vegetable origin, or independently by means of chemical
22synthesis, or by combination of extraction and chemical
23synthesis:
24        (1) Opium and opiates, and any salt, compound,
25    derivative or preparation of opium or opiate, excluding
		SB3221	- 62 -	LRB104 20204 RLC 33655 b
1    apomorphine, dextrorphan, levopropoxyphene, nalbuphine,
2    nalmefene, naloxone, and naltrexone, and their respective
3    salts, but including the following:
4            (i) Raw Opium;
5            (ii) Opium extracts;
6            (iii) Opium fluid extracts;
7            (iv) Powdered opium;
8            (v) Granulated opium;
9            (vi) Tincture of opium;
10            (vii) Codeine;
11            (viii) Ethylmorphine;
12            (ix) Etorphine Hydrochloride;
13            (x) Hydrocodone;
14            (xi) Hydromorphone;
15            (xii) Metopon;
16            (xiii) Morphine;
17            (xiii.5) 6-Monoacetylmorphine;
18            (xiv) Oxycodone;
19            (xv) Oxymorphone;
20            (xv.5) Tapentadol;
21            (xvi) Thebaine;
22            (xvii) Thebaine-derived butorphanol.
23            (xviii) Methorphan, except drug products
24        containing dextromethorphan that may be dispensed
25        pursuant to a prescription order of a practitioner and
26        are sold in compliance with the safety and labeling
		SB3221	- 63 -	LRB104 20204 RLC 33655 b
1        standards as set forth by the United States Food and
2        Drug Administration, or drug products containing
3        dextromethorphan that are sold in solid, tablet,
4        liquid, capsule, powder, thin film, or gel form and
5        which are formulated, packaged, and sold in dosages
6        and concentrations for use as an over-the-counter drug
7        product. For the purposes of this Section,
8        "over-the-counter drug product" means a drug that is
9        available to consumers without a prescription and sold
10        in compliance with the safety and labeling standards
11        as set forth by the United States Food and Drug
12        Administration.
13        (2) Any salt, compound, isomer, derivative or
14    preparation thereof which is chemically equivalent or
15    identical with any of the substances referred to in
16    subparagraph (1), but not including the isoquinoline
17    alkaloids of opium;
18        (3) Opium poppy and poppy straw;
19        (4) Coca leaves and any salt, compound, isomer, salt
20    of an isomer, derivative, or preparation of coca leaves
21    including cocaine or ecgonine, and any salt, compound,
22    isomer, derivative, or preparation thereof which is
23    chemically equivalent or identical with any of these
24    substances, but not including decocainized coca leaves or
25    extractions of coca leaves which do not contain cocaine or
26    ecgonine (for the purpose of this paragraph, the term
		SB3221	- 64 -	LRB104 20204 RLC 33655 b
1    "isomer" includes optical[, positional] and geometric
2    isomers);
3        (5) Concentrate of poppy straw (the crude extract of
4    poppy straw in either liquid, solid or powder form which
5    contains the phenanthrine alkaloids of the opium poppy).
6    (c) Unless specifically excepted or unless listed in
7another schedule any of the following opiates, including their
8isomers, esters, ethers, salts, and salts of isomers, whenever
9the existence of these isomers, esters, ethers and salts is
10possible within the specific chemical designation, dextrorphan
11excepted:
12        (1) Alfentanil;
13        (1.1) Carfentanil;
14        (1.2) Thiafentanyl;
15        (2) Alphaprodine;
16        (3) Anileridine;
17        (4) Bezitramide;
18        (5) Bulk Dextropropoxyphene (non-dosage forms);
19        (6) Dihydrocodeine;
20        (7) Diphenoxylate;
21        (8) Fentanyl;
22        (9) Sufentanil;
23        (9.5) Remifentanil;
24        (10) Isomethadone;
25        (11) (Blank);
26        (12) Levorphanol (Levorphan);
		SB3221	- 65 -	LRB104 20204 RLC 33655 b
1        (13) Metazocine;
2        (14) Methadone;
3        (15) Methadone-Intermediate,
4    4-cyano-2-dimethylamino-4,4-diphenyl-1-butane;
5        (16) Moramide-Intermediate,
6    2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic
7    acid;
8        (17) Pethidine (meperidine);
9        (18) Pethidine-Intermediate-A,
10    4-cyano-1-methyl-4-phenylpiperidine;
11        (19) Pethidine-Intermediate-B,
12    ethyl-4-phenylpiperidine-4-carboxylate;
13        (20) Pethidine-Intermediate-C,
14    1-methyl-4-phenylpiperidine-4-carboxylic acid;
15        (21) Phenazocine;
16        (22) Piminodine;
17        (23) Racemethorphan;
18        (24) (Blank);
19        (25) Levo-alphacetylmethadol (some other names:
20    levo-alpha-acetylmethadol, levomethadyl acetate, LAAM).
21    (d) Unless specifically excepted or unless listed in
22another schedule, any material, compound, mixture, or
23preparation which contains any quantity of the following
24substances having a stimulant effect on the central nervous
25system:
26        (1) Amphetamine, its salts, optical isomers, and salts
		SB3221	- 66 -	LRB104 20204 RLC 33655 b
1    of its optical isomers;
2        (2) Methamphetamine, its salts, isomers, and salts of
3    its isomers;
4        (3) Phenmetrazine and its salts;
5        (4) Methylphenidate;
6        (5) Lisdexamfetamine.
7    (e) Unless specifically excepted or unless listed in
8another schedule, any material, compound, mixture, or
9preparation which contains any quantity of the following
10substances having a depressant effect on the central nervous
11system, including its salts, isomers, and salts of isomers
12whenever the existence of such salts, isomers, and salts of
13isomers is possible within the specific chemical designation:
14        (1) Amobarbital;
15        (2) Secobarbital;
16        (3) Pentobarbital;
17        (4) Pentazocine;
18        (5) Phencyclidine;
19        (6) Gluthethimide;
20        (7) (Blank).
21    (f) Unless specifically excepted or unless listed in
22another schedule, any material, compound, mixture, or
23preparation which contains any quantity of the following
24substances:
25        (1) Immediate precursor to amphetamine and
26    methamphetamine:
		SB3221	- 67 -	LRB104 20204 RLC 33655 b
1            (i) Phenylacetone
2        Some trade or other names: phenyl-2-propanone;
3        P2P; benzyl methyl ketone; methyl benzyl ketone.
4        (2) Immediate precursors to phencyclidine:
5            (i) 1-phenylcyclohexylamine;
6            (ii) 1-piperidinocyclohexanecarbonitrile (PCC).
7        (3) Nabilone.
8(Source: P.A. 100-368, eff. 1-1-18.)
9    (720 ILCS 570/208)  (from Ch. 56 1/2, par. 1208)
10    Sec. 208. (a) The controlled substances listed in this
11Section are included in Schedule III.
12    (b) Unless specifically excepted or unless listed in
13another schedule, any material, compound, mixture, or
14preparation which contains any quantity of the following
15substances having a stimulant effect on the central nervous
16system, including its salts, isomers (whether optical
17position, or geometric), and salts of such isomers whenever
18the existence of such salts, isomers, and salts of isomers is
19possible within the specific chemical designation;
20        (1) Those compounds, mixtures, or preparations in
21    dosage unit form containing any stimulant substances
22    listed in Schedule II which compounds, mixtures, or
23    preparations were listed on August 25, 1971, as excepted
24    compounds under Title 21, Code of Federal Regulations,
25    Section 308.32, and any other drug of the quantitative
		SB3221	- 68 -	LRB104 20204 RLC 33655 b
1    composition shown in that list for those drugs or which is
2    the same except that it contains a lesser quantity of
3    controlled substances;
4        (2) Benzphetamine;
5        (3) Chlorphentermine;
6        (4) Clortermine;
7        (5) Phendimetrazine.
8    (c) Unless specifically excepted or unless listed in
9another schedule, any material, compound, mixture, or
10preparation which contains any quantity of the following
11substances having a potential for misuse associated with a
12depressant effect on the central nervous system:
13        (1) Any compound, mixture, or preparation containing
14    amobarbital, secobarbital, pentobarbital or any salt
15    thereof and one or more other active medicinal ingredients
16    which are not listed in any schedule;
17        (2) Any suppository dosage form containing
18    amobarbital, secobarbital, pentobarbital or any salt of
19    any of these drugs and approved by the Federal Food and
20    Drug Administration for marketing only as a suppository;
21        (3) Any substance which contains any quantity of a
22    derivative of barbituric acid, or any salt thereof:
23        (3.1) Aprobarbital;
24        (3.2) Butabarbital (secbutabarbital);
25        (3.3) Butalbital;
26        (3.4) Butobarbital (butethal);
		SB3221	- 69 -	LRB104 20204 RLC 33655 b
1        (4) Chlorhexadol;
2        (5) Methyprylon;
3        (6) Sulfondiethylmethane;
4        (7) Sulfonethylmethane;
5        (8) Sulfonmethane;
6        (9) Lysergic acid;
7        (10) Lysergic acid amide;
8        (10.1) Tiletamine or zolazepam or both, or any salt of
9    either of them.
10    Some trade or other names for a tiletamine-zolazepam
11    combination product: Telazol.
12    Some trade or other names for Tiletamine:
13    2-(ethylamino)-2-(2-thienyl)-cyclohexanone.
14    Some trade or other names for zolazepam:
15    4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-
16    [3,4-e], [1,4]-diazepin-7(1H)-one, and flupyrazapon.
17        (11) Any material, compound, mixture or preparation
18    containing not more than 12.5 milligrams of pentazocine or
19    any of its salts, per 325 milligrams of aspirin;
20        (12) Any material, compound, mixture or preparation
21    containing not more than 12.5 milligrams of pentazocine or
22    any of its salts, per 325 milligrams of acetaminophen;
23        (13) Any material, compound, mixture or preparation
24    containing not more than 50 milligrams of pentazocine or
25    any of its salts plus naloxone HCl USP 0.5 milligrams, per
26    dosage unit;
		SB3221	- 70 -	LRB104 20204 RLC 33655 b
1        (14) Ketamine;
2        (15) Thiopental; [.]
3        (16) Xylazine.
4    (d) Nalorphine.
5    (d.5) Buprenorphine.
6    (e) Unless specifically excepted or unless listed in
7another schedule, any material, compound, mixture, or
8preparation containing limited quantities of any of the
9following narcotic drugs, or their salts calculated as the
10free anhydrous base or alkaloid, as set forth below:
11        (1) not more than 1.8 grams of codeine per 100
12    milliliters or not more than 90 milligrams per dosage
13    unit, with an equal or greater quantity of an isoquinoline
14    alkaloid of opium;
15        (2) not more than 1.8 grams of codeine per 100
16    milliliters or not more than 90 milligrams per dosage
17    unit, with one or more active non-narcotic ingredients in
18    recognized therapeutic amounts;
19        (3) (blank);
20        (4) (blank);
21        (5) not more than 1.8 grams of dihydrocodeine per 100
22    milliliters or not more than 90 milligrams per dosage
23    unit, with one or more active, non-narcotic ingredients in
24    recognized therapeutic amounts;
25        (6) not more than 300 milligrams of ethylmorphine per
26    100 milliliters or not more than 15 milligrams per dosage
		SB3221	- 71 -	LRB104 20204 RLC 33655 b
1    unit, with one or more active, non-narcotic ingredients in
2    recognized therapeutic amounts;
3        (7) not more than 500 milligrams of opium per 100
4    milliliters or per 100 grams, or not more than 25
5    milligrams per dosage unit, with one or more active,
6    non-narcotic ingredients in recognized therapeutic
7    amounts;
8        (8) not more than 50 milligrams of morphine per 100
9    milliliters or per 100 grams with one or more active,
10    non-narcotic ingredients in recognized therapeutic
11    amounts.
12    (f) Anabolic steroids, except the following anabolic
13steroids that are exempt:
14        (1) Androgyn L.A.;
15        (2) Andro-Estro 90-4;
16        (3) depANDROGYN;
17        (4) DEPO-T.E.;
18        (5) depTESTROGEN;
19        (6) Duomone;
20        (7) DURATESTRIN;
21        (8) DUO-SPAN II;
22        (9) Estratest;
23        (10) Estratest H.S.;
24        (11) PAN ESTRA TEST;
25        (12) Premarin with Methyltestosterone;
26        (13) TEST-ESTRO Cypionates;
		SB3221	- 72 -	LRB104 20204 RLC 33655 b
1        (14) Testosterone Cyp 50 Estradiol Cyp 2;
2        (15) Testosterone Cypionate-Estradiol Cypionate
3    injection; and
4        (16) Testosterone Enanthate-Estradiol Valerate
5    injection.
6    (g) Hallucinogenic substances.
7        (1) Dronabinol (synthetic) in sesame oil and
8    encapsulated in a soft gelatin capsule in a U.S. Food and
9    Drug Administration approved product. Some other names for
10    dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro-
11    6,6,9-trimethyl-3-pentyl-6H-dibenzo (b,d) pyran-1-ol) or
12    (-)-delta-9-(trans)-tetrahydrocannabinol.
13        (2) (Reserved).
14    (h) The Department may except by rule any compound,
15mixture, or preparation containing any stimulant or depressant
16substance listed in subsection (b) from the application of all
17or any part of this Act if the compound, mixture, or
18preparation contains one or more active medicinal ingredients
19not having a stimulant or depressant effect on the central
20nervous system, and if the admixtures are included therein in
21combinations, quantity, proportion, or concentration that
22vitiate the potential for misuse of the substances which have
23a stimulant or depressant effect on the central nervous
24system.
25(Source: P.A. 103-881, eff. 1-1-25.)
		SB3221	- 73 -	LRB104 20204 RLC 33655 b
1    (720 ILCS 570/309.1 new)
2    Sec. 309.1. Xylazine exemptions. Notwithstanding the 
3scheduling of xylazine as a Schedule III controlled substance, 
4xylazine shall not be considered a controlled substance when:
5        (1) used by licensed Illinois veterinarians dispensing 
6    or prescribing for, or administering to, a nonhuman 
7    species of a drug containing xylazine that has been 
8    approved by the U.S. Food and Drug Administration;
9        (2) used by licensed Illinois veterinarians dispensing 
10    or prescribing for, or administering to, a nonhuman 
11    species that is permissible under the Federal Food, Drug, 
12    and Cosmetic Act;
13        (3) manufactured, distributed, or used as an active 
14    pharmaceutical ingredient for manufacturing an animal drug 
15    approved under the Federal Food, Drug, and Cosmetic Act;
16        (4) used by a licensed certified euthanasia technician 
17    employed by a certified euthanasia agency; or
18        (5) used by a wildlife biologist engaged in legal or 
19    authorized fieldwork under the indirect supervision of a 
20    veterinarian.
21    Section 99. Effective date. This Act takes effect January
221, 2027.